You are here

Mesenchymal Stem Cells

Mesenchymal Stem Cells as Neural Therapeutics

A concise review article published recently in STEM CELLS Translational Medicine from Marcin Majka and Bogna Badyra (Jagiellonian University Medical College, Cracow, Poland)

MSC Secreted Factors – The New Player in the Battle Against Antibiotic-Resistant Bacteria

New research shows how MSC-secreted factors can impair biofilm formation by cutaneous wound‐related bacteria and disrupt mature biofilms via a protease‐dependent mechanism

Reviewing Glioblastoma-Mesenchymal Stem Cell Interactions

The unique properties of mesenchymal stem cells (MSCs) have made them an exciting resource for the treatment of a range of human conditions, including degenerative and inflammatory diseases, tissue damage, and cancer.

Magnetic Guidance Improves MSC Therapy

Although the systemic administration of mesenchymal stem cells (MSCs) ameliorates lung inflammation and attenuates fibrosis in experimental silicosis, MSC therapy fails to reverse collagen deposition and granuloma formation.

Notch and BMP-mediated Osteoblastogenesis

Stimulation via the canonical Notch ligand, Jagged1, or bone morphogenetic proteins (BMP) can induce the osteoblastic differentiation of bone-marrow-derived human mesenchymal stem cells (hMSC); however, the question as to how these two pathways lead to the same phenotypic outcome remains unanswered.

MSC Priming and Wound Healing

Mesenchymal stem cells (MSCs) can accelerate wound healing; however, the failure of MSCs or MSC‐conditioned medium to function in all cases suggests room for significant improvement.

MSCs in Lung Inflammatory Diseases and COVID-19

Immunomodulation through human mesenchymal stem cell (MSC) therapy represents a clinically relevant treatment approach that allows for allogeneic use and broad application in immune/inflammatory diseases. These include severe pulmonary injury and inflammatory conditions such as acute respiratory distress syndrome (ARDS), which is associated with bacterial and viral infections.

GDF11 Protects MSCs via YME1L

Growth differentiation factor 11 (GDF11) induces the fusion of mitochondrial networks in hypoxic mesenchymal stem cells (MSCs) through the ALK4/5‐p‐Smad2/3 pathway. Additionally, increased levels of the mitochondria protease YME1L rebalances OPA1 processing and inhibits mitochondrial fragmentation in hypoxic MSCs.

The Antioxidant Paradigm of MSC Therapy

The role of mesenchymal stem cells (MSCs) in ameliorating oxidative and nitrosative injury has received considerable attention in recent years. The reduction‐oxidation environment regulates a range of physiological and pathophysiological mechanisms in cellular biology, and the ability of MSCs to regulate reduction/oxidation is of considerable interest.

AD Treatment via Intranasally Delivered MSC-EVs

In an attempt to discover a possible treatment for Alzheimer's disease (AD), researchers led by Silvia Coco (University of Milano‐Bicocca, Monza, Italy) have in


Subscribe to RSS - Mesenchymal Stem Cells